08:55:00 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaFirst North Stockholm
Prostatype Genomics är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska gentester som används för identifiering, analys och vidare uppföljning av prostatacancer. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden.


2022-02-24 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-08-18 Kvartalsrapport 2021-Q2
2021-06-17 Ordinarie utdelning PROGEN 0.00 SEK
2021-06-16 Årsstämma 2021
2021-05-27 Kvartalsrapport 2021-Q1
2021-02-19 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2021-08-24 10:15:00

-Results of the study from Skåne University Hospital selected to present during American Urology Congress 2021

The American Urology Association congress 2021 is the largest and most important gathering of Urologists in the world, and Prostatype Genomics is very proud to share that one of our P-score clinical validation studies has been selected for presentation at the congress.

Lidi Xu, Chief Technology Officer at Prostatype Genomics comments "We are very happy to have received this nomination; over- and under- treatment of prostate cancer patients is common, and a significant problem for healthcare in general, but most of all for the patients. To present and discuss Prostatype® and the P-score in front of the world's leading urologists is a great opportunity to help optimize prostate cancer risk assessment".

Study from Skåne University Hospital
The study "P-score based on three embryonic stem cell genes improves prognostic evaluation for metastasis and death in prostate cancer - a retrospective validation study" comprised a cohort of 716 patients diagnosed with PCa using core needle biopsy from January 2008 to December 2010 at Skåne University hospital with a follow-up time 8-10 years after diagnosis. This is the first time to present the study results based on the ISUP grading system. P-score has shown significantly better prediction performance for prostate cancer-specific death and metastasis than EAU risk classification. In total, 30% of patients were reclassified to lower risk groups while 4% of patients to higher risk groups as compared to the EAU risk classification, implying a treatment decision change.

Fredrik Persson, CEO of Prostatype Genomics, comments; "We are very proud about this recognition, being selected by leading experts to present in front of the top urologists in the world is a fantastic opportunity, and a confirmation regarding the potential of the Prostatype® test. This is also a great opportunity to make the American market aware of Prostatype Genomics and what we can offer."